Servier receives European Commission marketing approval for leukemia drug

Published on May 12, 2023

Servier has received marketing approval from the European Commission (EC) for Tibsovo (ivosidenib tablets) to treat isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukaemia (AML) and IDH1-mutated cholangiocarcinoma.

Continue reading on website
Other news

Xequel Bio selects Societal CDMO to support clinical development of iNexin

May 12, 2023
Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

AARDEX Group partners with the Digital Medical Society's new project to improve user needs

May 12, 2023
AARDEX Group has joined forces with other industry companies to partner with a new project from The Digital Medical Society (DiMe) called Extending the Verification, Analytical Validation, and Clinical Validation â or V3+ Framework.